Pages

Custom Search

Search Mad Money Fund Blog

Loading...

Are You Buying Jim Cramer's Get Rich Carefully Book ?

Share Stock Picks

Monday, April 6, 2015

Dutch Gold Resources, Inc. (OTCMKTS:DGRI) Tries to Resurface as a Marijuana Stock / Dutch Gold Resources Enters Continuing Medical Education Market



Dutch Gold Resources, Inc. (OTCMKTS:DGRI) Tries to Resurface as a Marijuana Stock

Ever since 2014 and the unprecedented rush towards the marijuana industry started we have seen a plethora of dead pennystocks trying to live a second life thanks to it. And Dutch Gold Resources, Inc. (OTCMKTS:DGRI, DGRI message board) are just one of the latest additions to the group.

The company last caught our attention nearly two years ago in May 2012. Back then, as their name shows, DGRI were trying to make it big by mining for gold and other precious metals. Well, just one look at their chart is enough to determine that things have certainly not gone as planned. For almost the whole of 2013 their stock saw trading only occasionally while at the same time was firmly rooted at the bottom of the chart at $0.0001.

All it took though was one brief PR from a month ago announcing that DGRI is switching to the medical marijuana industry and the company started climbing up once again. Yesterday they surged by more than 84% and returned to $0.0035, price ranges last visited two years ago as we already said. So, let's see how prepared DGRI really is for this new endeavor.


In April 2013 they submitted a notification of late filing for the annual report for 2012 but sadly to this day there is no sign of that report. This leaves the quarterly report for the period ending September 30 2012 as the most current information we have for the company. But taking into account the lack of operations since then we doubt that the numbers have improved drastically:
$2212 cash
$65 thousand total current assets
$6.7 million total current liabilities
ZERO sales
$366 thousand net loss
The accumulated deficit at the time had already surpassed $23 million while the outstanding shares were sitting at 2.4 billion out of the 2.75 billion authorized. That number is more than likely much larger now especially when back in July 2012 the authorized amount was increased to 4 billion.

In the PR articles from last week the management team speaks about their intentions to file all the missing reports, to reduce all the debt on their balance sheet while at the same time focus their efforts on the financial side of the marijuana industry. Their website finance420.com is set to launch today which explains the extremely positive outcome of yesterday's session.
DGRI has been making a lot of rather encouraging promises but for now they have nothing to offer. The depressing financials, HRDNchart.pnglack of any current information and billions of issued shares should be enough to demand serious due diligence before any trades with their stock are attempted.

Last Friday we saw an almost identical story - DC Brands International, Inc. (OTCMKTS:HRDN), a triple-zero tea-making pennystock, surged up the chart after they too decided to offer financial services to the marijuana industry. For now the general hype may push both stock even higher but it won't last forever and anyone who stayed for too long stands to suffer massive losses

ATLANTA, GA--(Marketwired - Mar 31, 2015) - Dutch Gold Resources, Inc. (OTC PINK: DGRI) (the "Company") (http://dutchgoldinc.com) today announced that its subsidiary, Ascendant Therapeutics, Inc., entered the Continuing Medical Education market and will soon launch two accredited courses for healthcare providers in the United States and Canada.
The courses are directed at physicians and nurses who have a need to know about the therapeutic use of MMJ and CBD. The first course analyses the use of CBD on various disease states, and is arranged by systems of the body. The second course addresses the use of THC related therapies and is appropriate for healthcare providers in states that have legalized the use of MMJ.
The exploration of how cannabinoid receptors and phytocannabinoids interact in disease processes and the possibilities for prevention and medical management of disorders utilizing adjunctive Cannabidiol (CBD) from legal industrial hemp is critical for all health care practitioners, including physicians, nurse practitioners, nurses, chiropractors, and dentists. We are pleased to have developed CME courses that will give physicians and nurses ACCME credit for their education in this emerging field.
While the marketing of the CME courses will begin Q2 2015, the Company is pleased to announce that it has entered into an agreement that will provide scholarships for 1,500 physicians, resulting in revenue that will be booked for each quarter of 2015 and into 2016.
Further the Company plans to release each of the manuals that have been previously announced, one in April and one in May of 2015.
Forward-Looking Statements
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Dutch Gold Resources, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

Monday, December 29, 2014

Would you buy Shake Shack stock? $SHAK



They will take the burger, but not the stock, at least not just yet. Danny Meyer’s burger joint Shake Shack Inc. on Monday filed for an initial public offering to raise up to $100 million. But among dozens of people lined up in the near-freezing temperature outside the restaurant in Manhattan’s Theater District on Monday, the interest in the stock seems to be anything but sizzling hot Restaurateur Danny Meyer's burger joint Shake Shack Inc. on Monday filed for an initial public offering to raise up to $100 million.

Thursday, December 25, 2014

#MadMoneyFund top 2015 Wall Street stock picks





Elon Musk has lost more than $1 billion on his Tesla holdings alone in the last month. But the inspiration for Hollywood's "Iron Man" may be a lot happier next year, if Wall Street analysts are right.
Tesla shares are due for a 30 percent comeback in the next 12 months based on the average analyst price target of $269.25 compiled by FactSet. Only Wynn Resorts shares are due for a bigger rally among stocks in the Nasdaq 100 index, according to FactSet.

Tesla shares should top Google, Netflix, Apple and Priceline in 2015, according to the data.


Elon Musk has lost more than $1 billion on his Tesla holdings alone in the last month. But the inspiration for Hollywood's "Iron Man" may be a lot happier next year, if Wall Street analysts are right.
Tesla shares are due for a 30 percent comeback in the next 12 months based on the average analyst price target of $269.25 compiled by FactSet. Only Wynn Resorts shares are due for a bigger rally among stocks in the Nasdaq 100 index, according to FactSet.

Tesla shares should top Google, Netflix, Apple and Priceline in 2015, according to the data.

As the price of oil has collapsed since November, so have shares of Tesla as investors bet gas guzzlers will be back in style with lower gasoline prices. However, analysts are sticking by their bullish price targets for Tesla, seeing the electric car company as a high-end technology story and not an alternative energy story.

Five analysts have reiterated their price targets for Tesla this month, among them Pacific Crest's Brad Erickson on Thursday, who sees a 48 percent rally in the shares to $316 over the next 12 months.

"While TSLA is a momentum stock, investors have been baking in that lower oil prices will be certain to reduce demand for electric vehicles, regardless of pricing," Erickson wrote in the report. "The market is being predictably irrational, and this has created a much better entry point in TSLA."


Tesla shares actually topped $290 in September before oil's drop turned into a crash, so analysts believe they can certainly get there again as the price of oil stabilizes in 2015.

"The way I look at Tesla in my bullish view stems from the disruptive nature of their technology," Carter Driscoll of MLV, a New York-based investment bank, said in a phone interview. Driscoll still sees Tesla rising to $300 over the next 12 months, according to FactSet.

Since oil's slide accelerated a month ago, Tesla has been the second-worst performer in the tech-heavy Nasdaq 100 index, falling 17 percent, according to Kensho, a quantitative tool used by hedge funds (Wynn Resorts was the worst performer).

Tesla has never had a relationship with oil before this past month. With "1" equaling a mirror image with oil and "0" equaling no discernible trend whatsoever, Tesla shares have a 0.12 correlation with crude over the past two years, according to Kensho.


Musk owns 28.3 million shares of the company he co-founded, according to filings, giving his stake a value of about $6 billion based on Thursday's stock price. A month ago, his stake was worth more than $7.2 billion. "Iron Man" director Jon Favreau told Time magazine four years ago that Musk was the inspiration for the lead character in the film because of his creation of Tesla as well as solar company SolarCity and space explorer SpaceX.

"The stock has a very strong retail (trading) base so it can be volatile on a day-to-day basis," Driscoll said. "I don't think anything has changed. It's just become more attractive on a valuation basis."

Pacific Crest said valuation is "much more reasonable given growth" and, discounting risks, has reiterated its "outperform" rating and $316 price target on the stock.

Read MoreAn energy source NOT threatened by falling oil

The note added that Tesla is growing more than 12 times faster than its peer group, which includes Amazon and Apple, but is only trading with an enterprise value of 2.6 times its 2016 revenue.

Pacific Crest believes revenue of $11 billion to $12 billion in 2016 is well within Tesla's reach.
The stock trades at nine times sales, near its lowest valuation on that basis over the past five years, according to FactSet.

Along with the drop in oil, a delay in the introduction of its new Model X vehicle made for a perfect storm of negative news for the stock in the last month. Musk announced the delay with the company's third-quarter earnings report last month. But the Model X is still coming and it will still turn heads in 2015 like Apple and GoPro do with their new product releases, the Pacific Crest analyst wrote in his note.

These stocks (Apple, GoPro) hit highs every time a new product was announced, and Pacific Crest expects the Model X to launch sometime in the third quarter of 2015, giving ample time for Tesla stock to rise into that release.

Don't wait too long, the report said. "Tesla will sell everything it makes, for a very long time."

Stifel Nicolaus, which has the highest price target on Wall Street at $400, said pushing the Model X introduction out to 2015 was "most prudent" on Musk's part as there's no rush with no real pure electric luxury carmakers out there.
As the price of oil has collapsed since November, so have shares of Tesla as investors bet gas guzzlers will be back in style with lower gasoline prices. However, analysts are sticking by their bullish price targets for Tesla, seeing the electric car company as a high-end technology story and not an alternative energy story.

Share It

Buy Stock Market Tips